Drug Profile


Alternative Names: ABR-215050; TASQ

Latest Information Update: 13 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; Ipsen
  • Class Antineoplastics; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Calgranulin B modulators; Immunomodulators; Thrombospondin 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Suspended Multiple myeloma
  • Discontinued Gastric cancer; Hepatocellular carcinoma; Ovarian cancer; Prostate cancer; Renal cancer

Most Recent Events

  • 02 Jun 2017 Additional efficacy data from a phase III trial in Prostate cancer presented at the American Society of Clinical Oncology Annual Meeting (ASCO-2017)
  • 27 Apr 2017 Active Biotech has patent protection for Tasquinimod in Europe
  • 12 Apr 2017 Tasquinimod receives Orphan Drug status for Multiple myeloma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top